2024
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen A, Hajduk A, Grimshaw A, Fried T, Jastreboff A, Lipska K. Efficacy of antiobesity medications for weight reduction in older adults: a systematic review. Obesity 2024 PMID: 39725567, PMCID: PMC12198421, DOI: 10.1002/oby.24160.Peer-Reviewed Original ResearchOlder adultsAntiobesity medicationsStudy of older adultsOlder adults ageAdult ageCardiovascular diseaseRisk of biasAdverse events associated with useWeight reductionStatistically significant weight reductionFood and Drug AdministrationClinical careSystematic reviewInclusion criteriaLimited evidenceBaseline weightPlacebo groupObservational studySeven medicationsAdverse eventsAdultsDrug AdministrationEvaluation studiesMedicationSignificant weight reductionConsiderations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
Kelly A, Bahlke M, Baker J, de Beaufort C, Belin R, Fonseca H, Hale P, Holm J, Hsia D, Jastreboff A, Juliusson P, Murphy M, Pak J, Paul E, Rudolph B, Srivastava G, Tornøe C, Weghuber D, Fox C. Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings. Pediatric Obesity 2024, 19: e13161. PMID: 39289849, DOI: 10.1111/ijpo.13161.Peer-Reviewed Original ResearchAnti-obesity medicationsExcessive weight reductionClinical trialsEnd pointsDown-titrationEligibility criteriaLong-term health outcomesBMI z-scoreActive comparatorEfficacy end pointPlacebo-controlled trialSecondary end pointsRun-in phaseFollow-up periodFollow-up phaseHealth outcomesObesity expertsTrial eligibility criteriaClinical careWeight reductionMultidisciplinary groupClinical trial protocolsPrimary outcomeWeight regainTrial protocolEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2
2023
A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management
Chetty A, Rafi E, Bellini N, Buchholz N, Isaacs D. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Endocrine Practice 2023, 30: 292-303. PMID: 38122931, DOI: 10.1016/j.eprac.2023.12.010.Peer-Reviewed Original ResearchConceptsWeight-related complicationsGlucose-dependent insulinotropic polypeptideReceptor agonistsIncretin therapiesGlucagon-like peptide-1Weight managementObesity managementLate-stage developmentOral GLP-1 receptor agonistSide effectsAssociated with weight regainReview clinical trial dataGLP-1 receptor agonistsDual GLP-1/GIP receptor agonistsGLP-1/GIP receptor agonistsWeeks of treatmentGastrointestinal side effectsClinical trial dataLevels of weight lossWeight reductionCombination therapyWeight regainClinical trialsTherapyPeptide-1Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeks
2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2018
Does food addiction contribute to excess weight among clinic patients seeking weight reduction? Examination of the Modified Yale Food Addiction Survey
Masheb RM, Ruser CB, Min KM, Bullock AJ, Dorflinger LM. Does food addiction contribute to excess weight among clinic patients seeking weight reduction? Examination of the Modified Yale Food Addiction Survey. Comprehensive Psychiatry 2018, 84: 1-6. PMID: 29654930, DOI: 10.1016/j.comppsych.2018.03.006.BooksConceptsYale Food Addiction ScaleExcess weightFood addictionClinic patientsWeight lossWeight management settingsOverweight/obesityWeight management programAlcohol use disorderBinge Eating DisorderVariance of BMIWeight reductionComorbid overweightPatient populationClinic settingNight eatingClinical significanceUse disordersDiagnostic thresholdPatientsAfflicted individualsMental healthEating DisordersDisorder pathologyBMI
2016
The Effect of Body Mass Index on Pelvic Floor Support 1 Year Postpartum
Chen Y, Johnson B, Li F, King WC, Connell KA, Guess MK. The Effect of Body Mass Index on Pelvic Floor Support 1 Year Postpartum. Reproductive Sciences 2016, 23: 234-238. PMID: 26494698, DOI: 10.1177/1933719115602769.Peer-Reviewed Original ResearchConceptsBody mass indexPelvic organ prolapseMass indexYear postpartumOrgan prolapsePelvic organ prolapse quantification systemElevated body mass indexPostpartum weight reductionUnlabored cesarean deliveryTrial of laborCesarean deliveryNulliparous womenThird trimesterFetal weightHigher oddsWomenProlapsePostpartumWeight reductionBaselineQuantification systemDeliveryTrimesterPOP assessmentPrevalence
2014
Mo1803 Blood Transfusion Among Patients Undergoing Elective Bariatric Surgery for Weight Reduction: A Nationwide Perspective
Augustin T, Steele K, Brethauer S, Canner J, Schneider E. Mo1803 Blood Transfusion Among Patients Undergoing Elective Bariatric Surgery for Weight Reduction: A Nationwide Perspective. Gastroenterology 2014, 146: s-1075. DOI: 10.1016/s0016-5085(14)63920-2.Peer-Reviewed Original Research
2012
Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes
Petersen KF, Dufour S, Morino K, Yoo PS, Cline GW, Shulman GI. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 8236-8240. PMID: 22547801, PMCID: PMC3361376, DOI: 10.1073/pnas.1205675109.Peer-Reviewed Original ResearchConceptsMuscle insulin resistanceInsulin-resistant offspringType 2 diabetesBranched-chain amino acidsInsulin resistanceIR offspringInsulin-stimulated muscle glucose uptakeWeight lossPeripheral insulin responsivenessReduction of IMCLModest weight lossPeripheral glucose metabolismC-reactive proteinHyperinsulinemic-euglycemic clampIntramyocellular lipid accumulationMuscle glucose uptakeAverage weight lossWeight reductionTotal adiponectinHypocaloric dietIL-6IMCL contentPlasma concentrationsWeight stabilizationIMCL accumulationManaging Medication Effects on Body Weight: Do Behavioral Interventions Work?
Ratliff J, Reutenauer E, Tek C. Managing Medication Effects on Body Weight: Do Behavioral Interventions Work? FOCUS The Journal Of Lifelong Learning In Psychiatry 2012, 10: 130-139. DOI: 10.1176/appi.focus.10.2.130.Peer-Reviewed Original ResearchBody weightMental illnessBehavioral modification interventionsSevere mental illnessQuality of lifeLifestyle interventionPsychotropic medicationsMedication effectsObesity riskPsychiatric symptomsPsychiatric careCognitive impairmentModification interventionsAvailable evidenceBehavioral interventionsObesityInterventionWeight reductionBehavioral changesIllnessRiskMedicationsPatientsSymptomsDiagnosis
2011
Kids and Adults Now! Defeat Obesity (KAN-DO): Rationale, design and baseline characteristics
Østbye T, Zucker NL, Krause KM, Lovelady CA, Evenson KR, Peterson BL, Bastian LA, Swamy GK, West DG, Brouwer RJ. Kids and Adults Now! Defeat Obesity (KAN-DO): Rationale, design and baseline characteristics. Contemporary Clinical Trials 2011, 32: 461-469. PMID: 21300177, PMCID: PMC3087307, DOI: 10.1016/j.cct.2011.01.017.Peer-Reviewed Original ResearchConceptsHealthy lifestyle changesPublic health priorityBehavioral intervention trialSingle group sessionHealth behavior changeObese mothersBaseline characteristicsHealthy weightOverweight childrenWeight maintenanceIntervention trialsChildhood obesityCounseling callsChild weightHealth priorityLifestyle changesFeeding practicesHealthy behaviorsActivity opportunitiesObesityGroup sessionsWeight reductionBehavioral changesTeachable momentChildren
2010
Energy intake in weight-reduced humans
Rosenbaum M, Kissileff HR, Mayer LE, Hirsch J, Leibel RL. Energy intake in weight-reduced humans. Brain Research 2010, 1350: 95-102. PMID: 20595050, PMCID: PMC2926239, DOI: 10.1016/j.brainres.2010.05.062.Peer-Reviewed Original ResearchConceptsEnergy intakeWeight lossSustained weight lossSuccessful weight reductionAdipocyte-derived hormoneBody weight maintenanceEnergy expenditureBody composition changesBody energy storesWeight maintenanceBody fatnessBody weightNeuronal signalingIntakeWeight reductionBasis of weightEnergy storesMultiple changesLeptinWeightHormoneResponseMultiparity is Associated With High Motivation to Change Diet Among Overweight and Obese Postpartum Women
Bastian LA, Pathiraja VC, Krause K, Brouwer R, Swamy GK, Lovelady CA, Østbye T. Multiparity is Associated With High Motivation to Change Diet Among Overweight and Obese Postpartum Women. Women's Health Issues 2010, 20: 133-138. PMID: 20149971, PMCID: PMC2849268, DOI: 10.1016/j.whi.2009.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexDietDietary CarbohydratesDietary FatsDietary ProteinsFemaleFollow-Up StudiesHealth BehaviorHumansInfant, NewbornMaternal Nutritional Physiological PhenomenaMothersMotivationObesityPostpartum PeriodPregnancyRandomized Controlled Trials as TopicRegression AnalysisSurveys and QuestionnairesUnited StatesWomen's HealthYoung AdultConceptsObese postpartum womenPostpartum womenPrimigravid womenFirst pregnancyEffect of parityBody mass index categoriesActive Mothers PostpartumCohort of overweightPostpartum weight reductionWoman's first pregnancyThird of participantsMothers postpartumPotential confoundersThird pregnancyMultivariable modelIndex categoriesLogistic regressionPregnancyWeight gainWomenMore childrenDietOverweightObesityWeight reduction
2008
EFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS
Carr R, Erondu N, Gonzalez C, Gumbiner B, Musser B, Lu K, Capece R, Klein S, Ravussin E, Amatruda J, Heymsfield S. EFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS. Atherosclerosis Plus 2008, 9: 209. DOI: 10.1016/s1567-5688(08)70835-3.Peer-Reviewed Original Research
1995
The effects of weight reduction to ideal body weight on body fat distribution
Hendler R, Welle S, Statt M, Barnard R, Amatruda J. The effects of weight reduction to ideal body weight on body fat distribution. Metabolism 1995, 44: 1413-1416. PMID: 7476327, DOI: 10.1016/0026-0495(95)90139-6.Peer-Reviewed Original ResearchConceptsIdeal body weightSubcutaneous fat areaBody mass indexFat areaObese womenFat distributionObese subjectsBody fatBody weightUpper body fat distributionIntraabdominal fat areaObese control subjectsBody fat distributionPercent body fatHealth risk factorsWeight reductionObese groupMass indexHip ratioControl subjectsRisk factorsMetabolic disordersControl groupWeight lossObese
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply